Abstract
Objective: To study the cell effects of raloxifene on uterine and leiomyoma tissue in postmenopausal women. Design: Prospective, randomized, double-blind, placebo-controlled study. Setting: Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro, Italy. Patient(s): Forty postmenopausal women affected by uterine leiomyomas and selected for hysterectomy. Intervention(s): Treatment for three cycles of 28 days with raloxifene at a dose of 180 mg/day orally (raloxifene group) or placebo tablets (3 tablets/day orally) (placebo group). Main Outcome Measure(s): Uterine and leiomyoma dimensions were measured in each subject at entry and before surgery. On leiomyomas and homologous myometrium the proliferating cell nuclear antigen (PCNA)-positive cells/total cells (PCNA/TC) and the Bcl-2-positive cells/Bax-positive cells (Bcl-2/Bax) ratios (%), as proliferation and apoptotic indexes, respectively, were measured. Result(s): After treatment, uterine and leiomyoma sizes were significantly changed in comparison with baseline and the placebo group. PCNA/TC and Bcl-2/Bax ratios were significantly higher in leiomyomas than in homologous myometrium. A significant difference was detected in PCNA/TC between the myometrium of the raloxifene and control groups, whereas no difference was observed in the Bcl-2/Bax ratio. A significant difference in PCNA/TC and Bcl-2/Bax ratios was detected in leiomyoma tissue between the raloxifene group and controls. Conclusion(s): In postmenopausal women, raloxifene administration reduces uterine leiomyomas by exerting a cell antiproliferative and proapoptotic action.
| Original language | English |
|---|---|
| Pages (from-to) | 154-161 |
| Number of pages | 8 |
| Journal | Fertility and Sterility |
| Volume | 84 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jul 2005 |
Fingerprint
Keywords
- Apoptosis
- Bax
- Bcl-2
- Leiomyoma
- PCNA
- Raloxifene
- SERM
ASJC Scopus subject areas
- Obstetrics and Gynaecology
Cite this
Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women. / Palomba, Stefano; Orio, Francesco; Russo, Tiziana; Falbo, Angela; Tolino, Achille; Lombardi, Gaetano; Cimini, Vincenzo; Zullo, Fulvio.
In: Fertility and Sterility, Vol. 84, No. 1, 07.2005, p. 154-161.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women
AU - Palomba, Stefano
AU - Orio, Francesco
AU - Russo, Tiziana
AU - Falbo, Angela
AU - Tolino, Achille
AU - Lombardi, Gaetano
AU - Cimini, Vincenzo
AU - Zullo, Fulvio
PY - 2005/7
Y1 - 2005/7
N2 - Objective: To study the cell effects of raloxifene on uterine and leiomyoma tissue in postmenopausal women. Design: Prospective, randomized, double-blind, placebo-controlled study. Setting: Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro, Italy. Patient(s): Forty postmenopausal women affected by uterine leiomyomas and selected for hysterectomy. Intervention(s): Treatment for three cycles of 28 days with raloxifene at a dose of 180 mg/day orally (raloxifene group) or placebo tablets (3 tablets/day orally) (placebo group). Main Outcome Measure(s): Uterine and leiomyoma dimensions were measured in each subject at entry and before surgery. On leiomyomas and homologous myometrium the proliferating cell nuclear antigen (PCNA)-positive cells/total cells (PCNA/TC) and the Bcl-2-positive cells/Bax-positive cells (Bcl-2/Bax) ratios (%), as proliferation and apoptotic indexes, respectively, were measured. Result(s): After treatment, uterine and leiomyoma sizes were significantly changed in comparison with baseline and the placebo group. PCNA/TC and Bcl-2/Bax ratios were significantly higher in leiomyomas than in homologous myometrium. A significant difference was detected in PCNA/TC between the myometrium of the raloxifene and control groups, whereas no difference was observed in the Bcl-2/Bax ratio. A significant difference in PCNA/TC and Bcl-2/Bax ratios was detected in leiomyoma tissue between the raloxifene group and controls. Conclusion(s): In postmenopausal women, raloxifene administration reduces uterine leiomyomas by exerting a cell antiproliferative and proapoptotic action.
AB - Objective: To study the cell effects of raloxifene on uterine and leiomyoma tissue in postmenopausal women. Design: Prospective, randomized, double-blind, placebo-controlled study. Setting: Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro, Italy. Patient(s): Forty postmenopausal women affected by uterine leiomyomas and selected for hysterectomy. Intervention(s): Treatment for three cycles of 28 days with raloxifene at a dose of 180 mg/day orally (raloxifene group) or placebo tablets (3 tablets/day orally) (placebo group). Main Outcome Measure(s): Uterine and leiomyoma dimensions were measured in each subject at entry and before surgery. On leiomyomas and homologous myometrium the proliferating cell nuclear antigen (PCNA)-positive cells/total cells (PCNA/TC) and the Bcl-2-positive cells/Bax-positive cells (Bcl-2/Bax) ratios (%), as proliferation and apoptotic indexes, respectively, were measured. Result(s): After treatment, uterine and leiomyoma sizes were significantly changed in comparison with baseline and the placebo group. PCNA/TC and Bcl-2/Bax ratios were significantly higher in leiomyomas than in homologous myometrium. A significant difference was detected in PCNA/TC between the myometrium of the raloxifene and control groups, whereas no difference was observed in the Bcl-2/Bax ratio. A significant difference in PCNA/TC and Bcl-2/Bax ratios was detected in leiomyoma tissue between the raloxifene group and controls. Conclusion(s): In postmenopausal women, raloxifene administration reduces uterine leiomyomas by exerting a cell antiproliferative and proapoptotic action.
KW - Apoptosis
KW - Bax
KW - Bcl-2
KW - Leiomyoma
KW - PCNA
KW - Raloxifene
KW - SERM
UR - http://www.scopus.com/inward/record.url?scp=22244479042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22244479042&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2004.12.058
DO - 10.1016/j.fertnstert.2004.12.058
M3 - Article
C2 - 16009171
AN - SCOPUS:22244479042
VL - 84
SP - 154
EP - 161
JO - Fertility and Sterility
JF - Fertility and Sterility
SN - 0015-0282
IS - 1
ER -